Literature DB >> 26908570

Continuous Glucose Monitoring Adherence: Lessons From a Clinical Trial to Predict Outpatient Behavior.

Martin de Bock1, Matthew Cooper2, Adam Retterath2, Jennifer Nicholas3, Trang Ly4, Timothy Jones4, Elizabeth Davis4.   

Abstract

AIMS: This study reports continuous glucose monitoring (CGM) adherence patterns and contributing factors in patients who were part of a 6-month clinical trial using sensor augmented pump therapy with low glucose insulin suspension.
METHODS: CGM data from 38 patients using sensor augmented pump therapy for 6 months were analyzed. CGM adherence was defined by having a working sensor available and determined by the time it was switched on as a proportion of available time for the 6 month study period with allowance for practical CGM use. Age, gender, HbA1c, duration of diagnosis, capillary blood glucose testing frequency, sensor accuracy, and insulin pump alarm frequency were characterized and examined for an association with CGM adherence.
RESULTS: Overall CGM adherence was 75% (range: 35% to 96%), CGM adherence was demonstrated to fall after 9 to 11 weeks before reaching a steady rate. CGM adherence patterns showed substantial variation. Mean adherence differed (P < .01) between age groups 72% (<12 years), 69% (12-18 years), and 88% (≥18 years). Sensor accuracy predicted adherence, where every 1% decline in mean absolute difference in a given week was associated with a 0.5% decline in sensor adherence (P < .01). Gender, HbA1c, duration of diagnosis, capillary blood glucose testing frequency, and insulin pump alarm frequency were not associated with CGM adherence.
CONCLUSIONS: CGM adherence and patterns of use are individualized. However, a predictable fall in adherence at 9 to 11 weeks may present an opportunity for timed interventions to increase CGM use. Adolescent age and sensor accuracy predict CGM adherence.
© 2016 Diabetes Technology Society.

Entities:  

Keywords:  continuous glucose monitoring systems; hypoglycemia; insulin pump therapy; pediatrics; type 1 diabetes

Mesh:

Year:  2016        PMID: 26908570      PMCID: PMC5038543          DOI: 10.1177/1932296816633484

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  14 in total

1.  Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study.

Authors:  Satish Garg; Ronald L Brazg; Timothy S Bailey; Bruce A Buckingham; Robert H Slover; David C Klonoff; John Shin; John B Welsh; Francine R Kaufman
Journal:  Diabetes Technol Ther       Date:  2012-02-08       Impact factor: 6.118

2.  Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring.

Authors:  Dorothee Deiss; Jan Bolinder; Jean-Pierre Riveline; Tadej Battelino; Emanuele Bosi; Nadia Tubiana-Rufi; David Kerr; Moshe Phillip
Journal:  Diabetes Care       Date:  2006-12       Impact factor: 19.112

3.  Effectiveness of sensor-augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study.

Authors:  Robert H Slover; John B Welsh; Amy Criego; Stuart A Weinzimer; Steven M Willi; Michael A Wood; William V Tamborlane
Journal:  Pediatr Diabetes       Date:  2011-07-03       Impact factor: 4.866

4.  Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes.

Authors:  Richard M Bergenstal; William V Tamborlane; Andrew Ahmann; John B Buse; George Dailey; Stephen N Davis; Carol Joyce; Tim Peoples; Bruce A Perkins; John B Welsh; Steven M Willi; Michael A Wood
Journal:  N Engl J Med       Date:  2010-06-29       Impact factor: 91.245

5.  Continuous glucose monitoring and intensive treatment of type 1 diabetes.

Authors:  William V Tamborlane; Roy W Beck; Bruce W Bode; Bruce Buckingham; H Peter Chase; Robert Clemons; Rosanna Fiallo-Scharer; Larry A Fox; Lisa K Gilliam; Irl B Hirsch; Elbert S Huang; Craig Kollman; Aaron J Kowalski; Lori Laffel; Jean M Lawrence; Joyce Lee; Nelly Mauras; Michael O'Grady; Katrina J Ruedy; Michael Tansey; Eva Tsalikian; Stuart Weinzimer; Darrell M Wilson; Howard Wolpert; Tim Wysocki; Dongyuan Xing
Journal:  N Engl J Med       Date:  2008-09-08       Impact factor: 91.245

6.  The use of continuous glucose monitoring systems in a pediatric population with type 1 diabetes mellitus in real-life settings: the AWeSoMe Study Group experience.

Authors:  M Rachmiel; Z Landau; M Boaz; K Mazor Aronovitch; N Loewenthal; M Ben-Ami; Y Levy-Shraga; D Modan-Moses; A Haim; S Abiri; O Pinhas-Hamiel
Journal:  Acta Diabetol       Date:  2014-09-16       Impact factor: 4.280

7.  Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes.

Authors:  Tadej Battelino; Moshe Phillip; Natasa Bratina; Revital Nimri; Per Oskarsson; Jan Bolinder
Journal:  Diabetes Care       Date:  2011-02-19       Impact factor: 19.112

8.  Extension of Nakagawa & Schielzeth's R2GLMM to random slopes models.

Authors:  Paul Cd Johnson
Journal:  Methods Ecol Evol       Date:  2014-07-23       Impact factor: 7.781

9.  Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend study.

Authors:  Denis Raccah; Véronique Sulmont; Yves Reznik; Bruno Guerci; Eric Renard; Hélène Hanaire; Nathalie Jeandidier; Marc Nicolino
Journal:  Diabetes Care       Date:  2009-09-18       Impact factor: 19.112

10.  Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes.

Authors:  Roy W Beck; Bruce Buckingham; Kellee Miller; Howard Wolpert; Dongyuan Xing; Jennifer M Block; H Peter Chase; Irl Hirsch; Craig Kollman; Lori Laffel; Jean M Lawrence; Kerry Milaszewski; Katrina J Ruedy; William V Tamborlane
Journal:  Diabetes Care       Date:  2009-08-12       Impact factor: 19.112

View more
  8 in total

Review 1.  Moving Toward a Unified Platform for Insulin Delivery and Sensing of Inputs Relevant to an Artificial Pancreas.

Authors:  Anneke Graf; Sybil A McAuley; Catriona Sims; Johanna Ulloa; Alicia J Jenkins; Gayane Voskanyan; David N O'Neal
Journal:  J Diabetes Sci Technol       Date:  2016-12-13

2.  Pediatric Endocrinologists' Experiences With Continuous Glucose Monitors in Children With Type 1 Diabetes.

Authors:  Kristina M Derrick; Rubina A Heptulla
Journal:  J Diabetes Sci Technol       Date:  2018-05-29

3.  Decisions in the Psychology of Glucose Monitoring.

Authors:  Gérard Reach
Journal:  J Diabetes Sci Technol       Date:  2019-06-14

4.  Accuracy Assessment of the GlucoMen® Day CGM System in Individuals with Type 1 Diabetes: A Pilot Study.

Authors:  Daniel A Hochfellner; Amra Simic; Marlene T Taucher; Lea S Sailer; Julia Kopanz; Tina Pöttler; Julia K Mader
Journal:  Biosensors (Basel)       Date:  2022-02-09

Review 5.  Use of Continuous Glucose Monitoring in Youth-Onset Type 2 Diabetes.

Authors:  Christine L Chan
Journal:  Curr Diab Rep       Date:  2017-09       Impact factor: 4.810

6.  Healthcare Resource Waste Associated with Patient Nonadherence and Early Discontinuation of Traditional Continuous Glucose Monitoring in Real-World Settings: A Multicountry Analysis.

Authors:  Shengsheng Yu; Biju Varughese; Zhiyi Li; Pam R Kushner
Journal:  Diabetes Technol Ther       Date:  2018-06       Impact factor: 6.118

7.  First assessment of the performance of an implantable continuous glucose monitoring system through 180 days in a primarily adolescent population with type 1 diabetes.

Authors:  Ronnie Aronson; Alexander Abitbol; Katherine S Tweden
Journal:  Diabetes Obes Metab       Date:  2019-04-23       Impact factor: 6.577

Review 8.  Coming of age: the artificial pancreas for type 1 diabetes.

Authors:  Hood Thabit; Roman Hovorka
Journal:  Diabetologia       Date:  2016-06-30       Impact factor: 10.122

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.